Wnt/β-catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review)

41Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is the third most common malignant tumor in humans. Chemotherapy is used for the treatment of CRC. However, the effect of chemotherapy remains unsatisfactory due to drug resistance. Growing evidence has shown that the presence of highly metastatic tumor stem cells, regulation of non-coding RNAs and the tumor microenvironment contributes to drug resistance mechanisms in CRC. Wnt/β-catenin signaling mediates the chemoresistance of CRC in these three aspects. Therefore, the present study analyzed the abundant evidence of the contribution of Wnt/β-catenin signaling to the development of drug resistance in CRC and discussed its possible role in improving the chemosensitivity of CRC, which may provide guidelines for its clinical treatment.

Cite

CITATION STYLE

APA

ZHU, G. X., GAO, D., SHAO, Z. Z., CHEN, L., DING, W. J., & YU, Q. F. (2021, February 1). Wnt/β-catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review). Molecular Medicine Reports. Spandidos Publications. https://doi.org/10.3892/mmr.2020.11744

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free